A novel macrocyclic tetrapeptide mimetic that exhibits low-picomolar Grb2 SH2 domain-binding affinity.

The growth factor receptor-bound protein 2 (Grb2) is an SH2 domain-containing docking module that participates in the signaling of numerous oncogenic growth factor receptor protein-tyrosine kinases (PTKs). Presented herein is a 5-methylindolyl-containing macrocyclic tetrapeptide mimetic (5) that binds to Grb2 SH2 domain protein with K(d)=75 pM. This represents the highest affinity yet reported for a synthetic inhibitor against any SH2 domain. In whole cell assays this novel analogue is able to effectively block the association of Grb2 to cognate cytoplasmic erbB-2 at IC(50)<10nM without prodrug derivatization or the addition of carrier peptide motifs. Anti-mitogenic effects against erbB-2-dependent breast cancers are achieved at non-cytotoxic concentrations (IC(50)=0.6 microM). Macrocycle 5 may be representative of a new class of therapeutically relevant Grb2 SH2 domain-directed agents.

[1]  Alexander Levitzki,et al.  Protein tyrosine kinase inhibitors as novel therapeutic agents. , 1999, Pharmacology & therapeutics.

[3]  L. Ellis,et al.  Development of SU5416, a selective small molecule inhibitor of VEGF receptor tyrosine kinase activity, as an anti-angiogenesis agent. , 2000, Anti-cancer drug design.

[4]  P. Renhowe.  Chapter 11. Growth factor receptor kinases in cancer , 2001 .

[5]  T. Burke,et al.  Inhibition of Grb2 SH2 domain binding by non-phosphate-containing ligands. 2. 4-(2-Malonyl)phenylalanine as a potent phosphotyrosyl mimetic. , 2000, Journal of medicinal chemistry.

[6]  Z. Yao,et al.  Potent Blockade of Hepatocyte Growth Factor-stimulated Cell Motility, Matrix Invasion and Branching Morphogenesis by Antagonists of Grb2 Src Homology 2 Domain Interactions* , 2001, The Journal of Biological Chemistry.

[7]  G. Milne,et al.  Potent inhibition of Grb2 SH2 domain binding by non-phosphate-containing ligands. , 1999, Journal of medicinal chemistry.

[8]  Gabriel Waksman,et al.  Molecular recognition by SH2 domains. , 2002, Advances in protein chemistry.

[9]  M. Moran,et al.  Grb2 and Shc Adapter Proteins Play Distinct Roles in Neu (ErbB-2)-Induced Mammary Tumorigenesis: Implications for Human Breast Cancer , 2001, Molecular and Cellular Biology.

[10]  G. Müller.  Peptidomimetic SH2 Domain Antagonists for Targeting Signal Transduction , 2000 .

[11]  Dajun Yang,et al.  Macrocyclization in the design of Grb2 SH2 domain-binding ligands exhibiting high potency in whole-cell systems. , 2003, Journal of medicinal chemistry.

[12]  Selective GRB2 SH2 inhibitors as anti‐Ras therapy , 1999, International journal of cancer.

[13]  S. Feller,et al.  High Affinity Molecules Disrupting GRB2 Protein Complexes as a Therapeutic Strategy for Chronic Myelogenous Leukaemia , 2003, Leukemia & lymphoma.

[14]  F. Walsh,et al.  Selective Inhibition of Growth Factor-stimulated Mitogenesis by a Cell-permeable Grb2-binding Peptide* , 1997, The Journal of Biological Chemistry.

[15]  S. Jakes,et al.  Determination of receptor-ligand kinetic and equilibrium binding constants using surface plasmon resonance: application to the lck SH2 domain and phosphotyrosyl peptides. , 1995, Journal of medicinal chemistry.

[16]  D. Myszka,et al.  CLAMP: a biosensor kinetic data analysis program. , 1998, Trends in biochemical sciences.

[17]  D G Myszka,et al.  Extending the range of rate constants available from BIACORE: interpreting mass transport-influenced binding data. , 1998, Biophysical journal.

[18]  Dajun Yang,et al.  Concise and enantioselective synthesis of Fmoc-Pmp(But)2-OH and design of potent Pmp-containing Grb2-SH2 domain antagonists. , 2003, Organic letters.

[19]  D. Erdmann,et al.  Structural basis for specificity of GRB2-SH2 revealed by a novel ligand binding mode , 1996, Nature Structural Biology.

[20]  P. Furet,et al.  Structure-based design of compounds inhibiting Grb2-SH2 mediated protein-protein interactions in signal transduction pathways. , 2000, Current pharmaceutical design.

[21]  H Roos,et al.  Biosensor analysis of the interaction between immobilized human serum albumin and drug compounds for prediction of human serum albumin binding levels. , 2000, Journal of medicinal chemistry.

[22]  P. Furet,et al.  Structure-based design and synthesis of high affinity tripeptide ligands of the Grb2-SH2 domain. , 1998, Journal of medicinal chemistry.

[23]  Pascal Furet,et al.  Tyrosine kinase inhibitors: From rational design to clinical trials , 2001, Medicinal research reviews.

[24]  W C Shakespeare.  SH2 domain inhibition: a problem solved? , 2001, Current opinion in chemical biology.

[25]  J. M. Bradshaw,et al.  Investigation of phosphotyrosine recognition by the SH2 domain of the Src kinase. , 1999, Journal of molecular biology.

[26]  R. V. van Etten,et al.  The Grb2 binding site is required for the induction of chronic myeloid leukemia-like disease in mice by the Bcr/Abl tyrosine kinase. , 2000, Blood.

[27]  B. Roques,et al.  Inhibitors of Ras signal transduction as antitumor agents. , 2000, Biochemical pharmacology.

[28]  T. Burke,et al.  Macrocyclization in the design of a conformationally constrained Grb2 SH2 domain inhibitor. , 2001, Bioorganic & medicinal chemistry letters.

[29]  D. Myszka,et al.  Improving biosensor analysis , 1999, Journal of molecular recognition : JMR.

[30]  G. Milne,et al.  Monocarboxylic-based phosphotyrosyl mimetics in the design of GRB2 SH2 domain inhibitors. , 1999, Bioorganic & medicinal chemistry letters.

[31]  Yao-Zhong Lin,et al.  Controlling Epidermal Growth Factor (EGF)-stimulated Ras Activation in Intact Cells by a Cell-permeable Peptide Mimicking Phosphorylated EGF Receptor* , 1996, The Journal of Biological Chemistry.

[32]  T. Burke,et al.  Olefin metathesis in the design and synthesis of a globally constrained Grb2 SH2 domain inhibitor. , 2001, Organic Letters.

[33]  T. Burke,et al.  N-terminal carboxyl and tetrazole-containing amides as adjuvants to Grb2 SH2 domain ligand binding. , 2001, Bioorganic & medicinal chemistry.

[34]  R. Sutherland,et al.  Overexpression of the Grb2 gene in human breast cancer cell lines. , 1994, Oncogene.

[35]  Dajun Yang,et al.  Development of a phosphatase-stable phosphotyrosyl mimetic suitably protected for the synthesis of high-affinity Grb2 SH2 domain-binding ligands. , 2002, Bioorganic & medicinal chemistry letters.

[36]  D. Fabbro,et al.  Effect of Potent and Selective Inhibitors of the Grb2 SH2 Domain on Cell Motility* , 1999, The Journal of Biological Chemistry.

[37]  C. Heldin,et al.  Involvement of platelet-derived growth factor in disease: development of specific antagonists. , 2001, Advances in cancer research.

[38]  D. Kamikura,et al.  Pathways Downstream of Shc and Grb2 Are Required for Cell Transformation by the Tpr-Met Oncoprotein* , 1996, The Journal of Biological Chemistry.

[39]  A. Tari,et al.  GRB2: a pivotal protein in signal transduction. , 2001, Seminars in oncology.

[40]  T Pawson,et al.  SH2 domains, interaction modules and cellular wiring. , 2001, Trends in cell biology.

[41]  Antagonists of the Src homology 2 (SH2) domains of Grb2, Src, Lck and ZAP-70. , 2001, Current medicinal chemistry.

[42]  M. Vidal,et al.  Inhibition of the ras-dependent mitogenic pathway by phosphopeptide prodrugs with antiproliferative properties. , 2000, Bioorganic & medicinal chemistry letters.

[43]  S. Wilkinson,et al.  Selective tyrosine kinase inhibitors , 2000 .